WO2002073209A3 - Verfahren zur identifikation von immunreaktiven epitopen auf proteinen - Google Patents

Verfahren zur identifikation von immunreaktiven epitopen auf proteinen Download PDF

Info

Publication number
WO2002073209A3
WO2002073209A3 PCT/EP2002/002629 EP0202629W WO02073209A3 WO 2002073209 A3 WO2002073209 A3 WO 2002073209A3 EP 0202629 W EP0202629 W EP 0202629W WO 02073209 A3 WO02073209 A3 WO 02073209A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
amino acids
proteins
peptides
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/002629
Other languages
English (en)
French (fr)
Other versions
WO2002073209A2 (de
Inventor
Rudolf Kunze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFINA IMMUNTECHNIK GmbH
Original Assignee
AFFINA IMMUNTECHNIK GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFFINA IMMUNTECHNIK GmbH filed Critical AFFINA IMMUNTECHNIK GmbH
Priority to AU2002302410A priority Critical patent/AU2002302410A1/en
Priority to EP02729986A priority patent/EP1410037A2/de
Publication of WO2002073209A2 publication Critical patent/WO2002073209A2/de
Publication of WO2002073209A3 publication Critical patent/WO2002073209A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Verfahren zur Identifikation von immunreaktiven Epitopen auf Proteinen von humanen Zellen, Geweben, Organen und von Mikrooganismen, die mit Erkrankungen wie Autoimmunerkrankungen, Krebserkrankungen oder Infektionen in Zusammenhang stehen, wobei Proben a) von Patienten mit diesen Erkrankungen aufgearbeitet werden, um Fraktionen zu erhalten, in denen Fa'b'-Antikörperfragmente und/oder Antigen erkennende Immunglobulinfragmente angereichert oder isoliert vorliegen, b) die im Schritt (a) angereicherten oder isolierten Fraktionen mit Peptiden, die mindestens zwölf Aminosäuren aufweisen und an einem Träger immobilisiert sind, in Kontakt gebracht werden, die durch Fragmentierung aus Proteinen oder Proteomen gewonnen werden, c) in einem Assay, bei dem Peptide mit mehr als zwölf Aminosäuren an Festphasen gebunden auf Wechselwirkung mit Fa'b'-Antikörperfragmenten und/oder Antigen erkennenden Immunglobulinfragmenten geprüft werden, woraufhin d) sich bei Wechselwirkungen zwischen den Fa'b'-Antikörperfragmenten und/oder Antigen erkennenden Immunglobulinfragmenten und dem mindestens zwölf Aminosäuren aufweisenden Peptid, das mindestens zwölf Aminosäuren aufweisende Peptid als immunreaktives Epitop zu erkennen gibt und ggf. weiter analysiert wird.
PCT/EP2002/002629 2001-03-10 2002-03-09 Verfahren zur identifikation von immunreaktiven epitopen auf proteinen Ceased WO2002073209A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002302410A AU2002302410A1 (en) 2001-03-10 2002-03-09 Method for identifying immune reactive epitopes on proteins
EP02729986A EP1410037A2 (de) 2001-03-10 2002-03-09 Verfahren zur identifikation von immunreaktiven epitopen auf proteinen und verwendung der epitope zu prophylaktischen und therapeutischen zwecken

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105989 2001-03-10
EP01105989.6 2001-03-10

Publications (2)

Publication Number Publication Date
WO2002073209A2 WO2002073209A2 (de) 2002-09-19
WO2002073209A3 true WO2002073209A3 (de) 2003-03-13

Family

ID=8176743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002629 Ceased WO2002073209A2 (de) 2001-03-10 2002-03-09 Verfahren zur identifikation von immunreaktiven epitopen auf proteinen

Country Status (3)

Country Link
EP (1) EP1410037A2 (de)
AU (1) AU2002302410A1 (de)
WO (1) WO2002073209A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160524A (zh) * 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
CA2764153C (en) 2009-06-02 2021-07-27 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
US8759259B2 (en) 2009-10-16 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565325A (en) * 1992-10-30 1996-10-15 Bristol-Myers Squibb Company Iterative methods for screening peptide libraries
WO2000029851A1 (en) * 1998-11-13 2000-05-25 Pepscan Systems B.V. A method for determining a mimotope sequence

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383002T3 (es) * 1998-01-30 2012-06-15 Allertein Therapeutics, Llc Prueba pronóstica de alergia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565325A (en) * 1992-10-30 1996-10-15 Bristol-Myers Squibb Company Iterative methods for screening peptide libraries
WO2000029851A1 (en) * 1998-11-13 2000-05-25 Pepscan Systems B.V. A method for determining a mimotope sequence

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLUETHNER M ET AL: "IDENTIFICATION OF MAJOR LINEAR EPITOPES ON THE SP100 NUCLEAR PBC AUTOANTIGEN BY THE GENE-FRAGMENT PHAGE-DISPLAY TECHNOLOGY", AUTOIMMUNITY, HARWOOD, CHUR, CH, vol. 29, no. 1, 1999, pages 33 - 42, XP001058410, ISSN: 0891-6934 *
GEVORKIAN G ET AL: "IMMUNODOMINANT SYNTHETIC PEPTIDES OF TAENIA CRASSICEPS IN MURINE AND HUMAN CYSTICERCOSIS", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 49, no. 3, 1996, pages 185 - 189, XP001058409, ISSN: 0165-2478 *
See also references of EP1410037A2 *
STEPHEN C W ET AL: "CHARACTERISATION OF EPITOPES ON HUMAN P53 USING PHAGE-DISPLAYED PEPTIDE LIBRARIES: INSIGHTS INTO ANTIBODY-PEPTIDE INTERACTIONS", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 248, 1995, pages 58 - 78, XP000619236, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
AU2002302410A1 (en) 2002-09-24
WO2002073209A2 (de) 2002-09-19
EP1410037A2 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
EP2311952A3 (de) Antikörper gegen MART-1 Protein oder Fragmenten davon
WO1995029193A3 (en) Melanoma antigens
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
WO2003045128A3 (en) SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
RU98118184A (ru) Пептидные иммуногены для вакцинации и лечения аллергии
EP2147928A3 (de) Auf Peptiden basierte Immunisierungstherapie zur Behandlung von Atherosklerose und Entwicklung von Peptid-basierten Assays zur Bestimmung von Immunreaktionen gegen oxidiertes Lipoprotein geringer Dichte
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
ATE244891T1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
EP2287177A3 (de) Streptococcus agalactiae-Antigene I + II
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
ID19063A (id) Pereaksi peptida untuk deteksi cytomegalovirus (cmv)
WO2001040281A3 (en) Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
WO2002073209A3 (de) Verfahren zur identifikation von immunreaktiven epitopen auf proteinen
WO2004039842A3 (en) Humanized tissue factor antibodies
Chen et al. Separation and characterization of a porcine‐specific thermostable muscle protein from cooked pork
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
Gruber et al. Development of an epitope‐specific analytical tool for the major peanut allergen Ara h 2 using a high‐density multiple‐antigenic peptide strategy
CA2454605A1 (en) Immunoaffinity isolation of modified peptides from complex mixtures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2002729986

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002729986

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP